ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The initial public offering market in pharmaceuticals received a double jolt last week with two firms filing for offerings in the range of $100 million. RegenXBio, a pioneer in gene therapy that has licensed its technology to other companies and is currently pursuing therapies on its own, launched a bid to raise $100 million in an IPO. Meanwhile, Edge Therapeutics, with a drug candidate for the treatment of brain injuries, set its sights on a $115 million launch. The company reported positive clinical results last week for its lead candidate, Newton, a nimodipine microparticle therapy to enhance recovery after subarachnoid hemorrhage.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X